Track market-moving stories before they get noisy

Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July

Posted by Defense World Staff on Jul 28th, 2026

Castleark Management LLC trimmed its position in shares of iRhythm Technologies (NASDAQ:IRTC – Free Report) by 45.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,193 shares of the company’s stock after selling 23,000 shares during the quarter. Castleark Management LLC owned 0.08% of iRhythm Technologies worth $3,209,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of IRTC. Granahan Investment Management LLC raised its stake in shares of iRhythm Technologies by 567.9% in the first quarter. Granahan Investment Management LLC now owns 96,022 shares of the company’s stock valued at $11,333,000 after acquiring an additional 81,645 shares during the period. Entropy Technologies LP boosted its stake in shares of iRhythm Technologies by 59.2% during the 1st quarter. Entropy Technologies LP now owns 10,652 shares of the company’s stock worth $1,257,000 after purchasing an additional 3,963 shares during the period. Inceptionr LLC grew its holdings in iRhythm Technologies by 58.2% during the 1st quarter. Inceptionr LLC now owns 5,420 shares of the company’s stock valued at $640,000 after purchasing an additional 1,993 shares during the last quarter. Group One Trading LLC bought a new position in iRhythm Technologies during the 1st quarter valued at about $206,000. Finally, WCM Investment Management LLC grew its holdings in iRhythm Technologies by 47.5% during the 1st quarter. WCM Investment Management LLC now owns 108,078 shares of the company’s stock valued at $12,344,000 after purchasing an additional 34,786 shares during the last quarter.

Wall Street Analysts Forecast Growth Several analysts have issued reports on IRTC shares. The Goldman Sachs Group decreased their price objective on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Truist Financial cut their target price on iRhythm Technologies from $174.00 to $160.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Bank of America reduced their price target on iRhythm Technologies from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, May 18th. JPMorgan Chase & Co. dropped their price objective on iRhythm Technologies from $215.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, Wells Fargo & Company cut their price objective on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, iRhythm Technologies has an average rating of “Buy” and a consensus target price of $184.71.

View Our Latest Report on iRhythm Technologies

iRhythm Technologies Trading Up 2.7% Shares of NASDAQ IRTC opened at $112.15 on Tuesday. iRhythm Technologies has a twelve month low of $100.85 and a twelve month high of $212.00. The firm has a market cap of $3.69 billion, a PE ratio of -130.41 and a beta of 1.27. The business has a fifty day simple moving average of $113.61 and a two-hundred day simple moving average of $127.38. The company has a quick ratio of 4.98, a current ratio of 5.17 and a debt-to-equity ratio of 4.03.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.21. The business had revenue of $199.39 million for the quarter, compared to the consensus estimate of $194.11 million. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The business’s revenue was up 25.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.97) EPS. Analysts expect that iRhythm Technologies will post 0.13 earnings per share for the current fiscal year.

Insider Buying and Selling In other iRhythm Technologies news, Director Abhijit Y. Talwalkar purchased 5,312 shares of iRhythm Technologies stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $10.71 per share, for a total transaction of $56,891.52. Following the acquisition, the director owned 25,611 shares in the company, valued at $274,293.81. This trade represents a 26.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.98% of the company’s stock.

iRhythm Technologies Company Profile (Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

Featured Articles Five stocks we like better than iRhythm Technologies AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEInvitation Home (INVH) Projected to Post Quarterly Earnings on Wednesday

NEXT HEADLINE »Vanguard High Dividend Yield ETF (NYSEARCA:VYM) Sets New 1-Year High – Should You Buy?

July 16, 2026 16:05 ET  | Source: iRhythm

SAN FRANCISCO, July 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the second quarter 2026 after the close of trading on Thursday, August 6, 2026. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
[email protected]

Media Contact
Kassandra Perry
[email protected]

, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. 

According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients. Specifically, that insiders repeatedly touted the potential growth for the Zio AT as an innovative product that had only just begun to penetrate the market for real-time monitoring, which investors looked upon favorably given the premium selling price associated with devices approved for high-risk patients. As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices at relevant times.

If you currently own IRTC and purchased prior to November 5, 2021 please contact Sophia Anne Silayan by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™ 

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

SOURCE Kuehn Law, PLLC

CompaniesJune 15 (Reuters) - iRhythm Holdings (IRTC.O), opens new tab on Monday reported unauthorized activity involving data maintained on some third-party applications last week, but said ​it has not identified any impact on products, ‌patient safety or medical device systems from the cyber attack.

Here are some details from the company's filing:

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The medtech firm said it identified ​unauthorized activity on June 8 and launched an ​investigation with external cybersecurity experts.

The company added that on ⁠June 9 it received a payment demand from a "threat ​actor" claiming to have obtained proprietary data, patient protected health ​information and other personal information.

iRhythm deemed the incident material on June 10 due to the volume of potentially affected data.

Based on current investigations, ​the incident does not have any impact on manufacturing ​and distribution operations, financial reporting systems or the company's ability to meet ‌patient ⁠needs, iRhythm said.

The affected data was obtained through social engineering and is from certain third-party-hosted business applications, it added .

iRhythm said the incident did not involve its clinical or medical ​device systems ​or customer connections, ⁠and that it does not store individual financial account or payment card information.

The company ​has not identified evidence of ongoing unauthorized access ​to ⁠its systems and continuing to investigate the nature and scope of the incident and who was affected, it added.

The incident ⁠is ​not likely to materially affect its ​financial condition or results, and cybersecurity insurance may cover some losses, The company ​said.

Reporting by Kunal Das in Bengaluru; Editing by Joyjeet Das

Our Standards: The Thomson Reuters Trust Principles., opens new tab

What happenedAccording to an SEC filing dated Feb. 17, 2026, RTW Investments disclosed a new position in iRhythm Holdings (IRTC +0.60%) after acquiring 1,181,990 shares during the fourth quarter. The fund’s quarter-end position in IRTC was valued at $210 million.

What else to knowThis is a new position for RTW Investments, representing 2.1% of its $9.98 billion 13F reportable assets under management as of Dec. 31, 2025.Top five holdings after the filing:NASDAQ:MDGL: $1.2 billion (11.6% of AUM)NASDAQ:INSM: $842.9 million (8.4% of AUM)NASDAQ:PTCT: $588.4 million (5.9% of AUM)NASDAQ:ARGX: $566.4 million (5.7% of AUM)NASDAQ:PTGX: $441.9 million (4.4% of AUM)As of March 19, 2026, shares of iRhythm Holdings were priced at $117.78, up 14.2% over the past year, underperforming the S&P 500 by 3.5 percentage points.Company OverviewMetricValueRevenue (TTM)$747.1 millionNet Income (TTM)-$44.6 millionPrice (as of market close Mar. 19, 2026)$117.78One-Year Price Change14.2%Company SnapshotOffers ambulatory ECG monitoring products, including the Zio XT and AT wearable patch-based biosensors, and a cloud-based data analytics platform for arrhythmia detection.Generates revenue primarily through sales of its Zio service, combining device sales with subscription-based monitoring and diagnostic services for healthcare providers.Targets healthcare institutions, physicians, and patients in the United States at risk for cardiac arrhythmias.iRhythm Holdings, Inc. is a digital healthcare company specializing in innovative cardiac monitoring solutions. Its core offering, the Zio platform, leverages wearable biosensors and advanced analytics to improve arrhythmia detection and diagnosis.

What this transaction means for investorsRTW Investments isn't a generalist fund making a casual bet -- it's a specialized healthcare and life sciences investor with deep sector expertise, which makes this move worth a closer look. Opening a brand-new position of this size signals real conviction: at roughly $210 million, the IRTC stake becomes RTW’s eleventh-largest holding -- representing about 2.1% of the fund's total 13F-reported portfolio -- a meaningful commitment from a manager that already holds concentrated positions in names like Madrigal Pharmaceuticals (MDGL +0.94%) and Insmed (INSM +1.43%).

iRhythm Holdings sits at an interesting intersection of medical devices and digital health. Its flagship Zio patch -- a discreet, wearable cardiac monitor -- has carved out a strong niche in ambulatory ECG monitoring, a market that's likely to grow as remote patient monitoring becomes more standard in cardiology. Unlike a traditional Holter monitor, the Zio system collects continuous data over days or weeks and runs it through a cloud-based analytics platform, giving physicians a much richer picture of a patient's heart rhythm. That combination of hardware, software, and services gives iRhythm a recurring revenue model that can be stickier than a simple device sale.

For retail investors interested in the digital health space, iRhythm represents a focused play on cardiac care innovation. Those who prefer broader exposure might also consider ETFs like the Health Care Select Sector SPDR Fund (XLV 0.10%) or the iShares U.S. Medical Devices ETF (IHI 0.13%), which provide diversified access to companies operating across health technology and medical devices. Either way, when a specialized healthcare fund with RTW's track record makes a move this size into a new name, it's a signal worth researching.

Andy Gould has positions in Argenx Se. The Motley Fool has positions in and recommends Argenx Se. The Motley Fool recommends Protagonist Therapeutics. The Motley Fool has a disclosure policy.

March 30, 2026 08:05 ET  | Source: iRhythm

Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ambulatory ECG portfolio.1,2
Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F. Bishop Keynote on scaling AI in cardiology and translating advances into clinical practice.
iRhythm Academy launch expands access to clinician education at scale in ambulatory cardiac monitoring as the field continues to advance.
SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC) announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions in New Orleans, March 28–30, 2026, that add to the growing body of clinical evidence supporting the benefits of its Zio® ambulatory ECG monitoring service across patient populations.1,2 The data provide insights into the timing and incidence of clinically relevant arrhythmias and highlight opportunities to improve care for patients along the cardiovascular-kidney-metabolic (CKM) continuum.

iRhythm also highlighted its leadership in advancing AI in cardiology, with Chief Medical Officer Mintu Turakhia, MD, MS, Clinical Professor of Medicine at Stanford University, delivering the 57th Annual Louis F. Bishop Keynote, titled “Scaling AI in Cardiology: Moving From Paper and Podium to Product,” and announced the launch of iRhythm Academy, a clinician education platform.

High Prevalence of Clinically Actionable Arrhythmias Across the CKM Continuum, Highlighting Increased Risk for Arrhythmias in this Patient Population

Two abstracts presented at ACC.26 reported the results of retrospective analyses of the incidence of arrhythmias in patients across the CKM disease continuum.3,4 Each study utilized data from the iRhythm clinical data warehouse linked to commercial fee-for-service and government-sponsored plans claims data. Findings from both studies enhance the understanding of how CKM risk factors influence the incidence of arrhythmias, highlighting that clinically relevant arrhythmias are not limited to patients with more advanced comorbid conditions or disease states.

Arrhythmias in Patients with Diabetes and Chronic Kidney Disease Detected by Long-Term Ambulatory ECG Monitoring3 (Abstract #1474-105) evaluated the prevalence of arrhythmias detected in a cohort of 657,147 individuals in the U.S. who received 14-day continuous ambulatory monitoring linked to commercial fee-for-service or Medicare Advantage claims. The cohort had a mean age of 59 years and was 58% female. Clinically actionable arrhythmias were more commonly identified in patients with chronic kidney disease (CKD), with or without diabetes:

11% of patients had diabetes, 4% had chronic kidney disease, and 4% had both conditions—together representing nearly 20% of the overall cohort.After accounting for differences in age, clinically actionable arrhythmias affected 48% of patients with CKD and 47% of patients with both diabetes and CKD, compared with 39% of patients with diabetes alone and 35% of patients with neither condition.Arrhythmia risk increased across kidney-metabolic phenotypes, highest in CKD (with or without diabetes), with diabetes alone also increasing risk—highlighting the value of targeted rhythm monitoring in patient populations at higher risk for arrhythmia.
Incidence of Arrhythmias in Patients with Obesity Detected by Long-Term Ambulatory ECG Monitoring4 (Abstract # 1403-107) evaluated the prevalence of arrhythmias of arrhythmias detected 162,531 individuals in the U.S. who received 14-day long-term continuous monitoring (LTCM) with Zio and where BMI or weight-related diagnostic codes were available. The cohort had a mean age of 58 years and was 65% female. Higher body weight was associated with greater likelihood of atrial fibrillation (AF) detection:

The prevalence of detected AF increased with weight, rising from 4.5% in normal/underweight patients to 6.5% in patients with severe obesity.After accounting for differences in age, sex, and comorbidities, patients with severe obesity had nearly threefold higher odds of AF detection compared with normal/underweight patients (adjusted odds ratio of 2.8).Nearly two-thirds of patients in this cohort had obesity or severe obesity, highlighting excess weight as a common and potentially modifiable risk factor for AF.
Expanding Evidence Highlights the Opportunity for Earlier Detection and Diagnosis

Data presented at ACC.26 build on prior real-world evidence demonstrating that arrhythmias are common, early, and often silent across cardiometabolic patient populations. Findings from two large-scale, real-world studies5,6 presented at the American Diabetes Association’s 85th Scientific Sessions in June 2025 (ADA 2025) demonstrated that arrhythmias preceded 43% of diabetes and 59% of CKD cases in the study population. Many patients in one study subsequently developed clinically actionable arrhythmia or major cardiovascular events. Three large-scale real-world analyses presented at the American Heart Association Scientific Sessions 2025 (AHA 2025)7-9 similarly revealed arrhythmia risk emerging earlier across the CKM syndrome continuum. These findings are extended by ACC.26 data demonstrating that the Zio ambulatory ECG service has a high diagnostic yield in these patient populations,3,4 enabling earlier identification of clinically actionable arrhythmias.

With an estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias each year,10 iRhythm is committed to reaching patients sooner and has been advancing a data-driven, proactive cardiac monitoring approach deployed with healthcare systems focused on population health management and value-based care goals. Building on this foundation, in 2025, iRhythm announced a collaboration with Lucem Health to apply predictive AI11 to flag patients at elevated risk for arrhythmias, including those with diabetes and CKD, enabling more targeted selection of patients for proactive monitoring and more timely diagnosis and clinical decision-making.

Scaling AI in Cardiology and Expanding Education at Scale

In addition to the data presentations at ACC.26, Mintu Turakhia, MD, MS, Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University, delivered the 57th Annual Louis F. Bishop Keynote, titled “Scaling AI in Cardiology: Moving From Paper and Podium to Product.” The keynote addressed the gap between advances in artificial intelligence and their translation into routine cardiovascular care.

Drawing on iRhythm’s platform, its application of advanced AI in cardiac monitoring, and 20-year history, Dr. Turakhia emphasized how AI must function as an infrastructural backbone—integrating multiple streams of data, extending AI to new clinical domains, operationalized within clinical workflows, and accountable for real-world outcomes.

“The primary barrier to impact is no longer technical development or model performance — most AI across diagnostics, clinical decision support, and other domains work well. We need to think of these tools not as point solutions or standalone tests, but rather as critical clinical infrastructure and integrated systems that are safely and responsibly deployed,” said Dr. Turakhia.

iRhythm also launched iRhythm Academy, an education platform offering interactive courses, webinars, publications, and micro-learning modules for healthcare professionals focused on ambulatory cardiac monitoring, extending access to education at scale as the field continues to advance.

iRhythm also announced an upcoming update to the MyZio® mobile app, which supports patients throughout their ECG monitoring journey with Zio, with the addition of Spanish-language functionality to support patient accessibility.12

Data presented at ACC.26 build on iRhythm’s comprehensive clinical evidence program, encompassing more than 135 original research manuscripts, insights derived from over 3 billion hours of curated heartbeat data, and nearly 12 million patient reports since the company’s inception13—underscoring its ongoing commitment to expanding evidence that supports improved patient outcomes.

About iRhythm Holdings
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “anticipate,” “estimate,” “expect,” “intend,” “will,” “may,” “project,” “plan,” “believe,” “target,” and similar expressions that relate to future events or outcomes.

Forward-looking statements in this press release include, but are not limited to, statements regarding the significance and potential impact of the data presented; the clinical utility and performance of iRhythm’s Zio® ambulatory ECG monitoring service; the potential to enable earlier detection and diagnosis of arrhythmias; the application of artificial intelligence and predictive analytics to identify patients at elevated risk for arrhythmias; and the ability to expand access to clinician education and improve patient care through initiatives such as iRhythm Academy.

These statements are based on current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the timing, interpretation, and acceptance of clinical data; the ability to translate findings into clinical practice; regulatory and reimbursement developments; market adoption of iRhythm’s products and services; and the risks described in the section entitled “Risk Factors” in iRhythm’s most recent filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q.

These forward-looking statements speak only as of the date of this press release, and iRhythm undertakes no obligation to update them, except as required by law.

Media Contact:
Kassandra Perry
[email protected]

Investor Contact:
Stephanie Zhadkevich
[email protected]

The Zio AT device is not intended for use in critical care patients because the reporting timeliness is not consistent with life-threatening arrhythmias such as ventricular fibrillation. Refer to Zio AT Clinical Reference Manual for additional information.Do not use Zio AT for patients with symptomatic episodes where variations in cardiac performance could result in immediate danger to the patient or when real-time or in-patient monitoring should be prescribed.Ashburner JM et al. “Arrhythmias in Patients with Diabetes and Chronic Kidney Disease Detected by Long-Term Ambulatory ECG Monitoring.” American College of Cardiology 2026 Annual Scientific Session & Expo, 2026. New Orleans, Louisiana.Battisti AJ. “Incidence of Arrhythmias in Patients with Obesity Detected by Long-Term Ambulatory ECG Monitoring.” American College of Cardiology 2026 Annual Scientific Session & Expo, 2026. New Orleans, Louisiana.“Incidence of Cardiac Arrhythmias in Patients with Diabetes: a Real-World Study.” American Diabetes Scientific Sessions, 2025; Chicago, Illinois.Russo P et al. “Incidence and Timing of Major Arrhythmias in T2D and CKD:A Real-World Analysis.” American Diabetes Scientific Sessions, 2025; Chicago, Illinois.Russo P et al. “Onset of Arrhythmias in the CKM Continuum: Real-World Insights From a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.Russo P et al. “CKD and CKM Syndrome: Accelerated Progression to Arrhythmias in a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.Russo P et al. “Arrhythmias as Early Predictors of Chronic Kidney Disease: Real-World Evidence From a National Cardio-Kidney-Metabolic Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.https://www.jacc.org/doi/10.1016/S0735-1097%2823%2902786 9 https://www.ajmc.com/view/assessment-of-variation-in-ambulatory-cardiac-monitoring-among-commercially-insured-patientsiRhythm internal estimate based on analysis of public and proprietary sources, including U.S. Census Bureau data, CDC healthcare utilization data, Medicare Public Use Files, IQVIA, Komodo Health, Definitive Healthcare, and peer-reviewed literature on arrhythmia prevalence, symptom presentation, and diagnostic pathways. Full source list available upon request.Predictive Arrhythmia Solutions does not represent functionality of any Zio branded medical device.The MyZio® mobile app for patients is not a medical device and is not intended to diagnose, treat, cure, or prevent any disease.Data on file. iRhythm Technologies, 2025.

Posted by Defense World Staff on Apr 6th, 2026

MSP Recovery (NASDAQ:MSPR – Get Free Report) and iRhythm Technologies (NASDAQ:IRTC – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability This table compares MSP Recovery and iRhythm Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets MSP Recovery -7,328.48% -326.80% -81.27% iRhythm Technologies -5.96% -28.15% -3.35% Analyst Ratings This is a breakdown of recent ratings for MSP Recovery and iRhythm Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MSP Recovery 1 0 0 0 1.00 iRhythm Technologies 1 1 11 2 2.93 iRhythm Technologies has a consensus target price of $209.46, indicating a potential upside of 79.33%. Given iRhythm Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than MSP Recovery.

Valuation and Earnings This table compares MSP Recovery and iRhythm Technologies”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MSP Recovery $9.81 million 0.05 -$360.50 million ($572.83) 0.00 iRhythm Technologies $747.14 million 5.05 -$44.55 million ($1.40) -83.43 iRhythm Technologies has higher revenue and earnings than MSP Recovery. iRhythm Technologies is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk MSP Recovery has a beta of -2.8, meaning that its stock price is 380% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Institutional & Insider Ownership 3.8% of MSP Recovery shares are held by institutional investors. 50.5% of MSP Recovery shares are held by insiders. Comparatively, 1.1% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary iRhythm Technologies beats MSP Recovery on 12 of the 15 factors compared between the two stocks.

About MSP Recovery (Get Free Report)

MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.

About iRhythm Technologies (Get Free Report)

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Receive News & Ratings for MSP Recovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MSP Recovery and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMacroGenics (NASDAQ:MGNX) & Medtronic (NYSE:MDT) Critical Review

NEXT HEADLINE »Contrasting Energys Group (NASDAQ:ENGS) & Brookfield Business (NYSE:BBUC)

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.

If you currently own iRhythm stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Our firm would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

April 27, 2026 08:05 ET  | Source: iRhythm

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations.1-2Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.1 SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC) today announced results from two real-world retrospective analyses in post-ablation and pregnancy patient populations presented at the Heart Rhythm Society’s annual meeting, HRS 2026, held April 23–26 in Chicago. Across both studies, arrhythmias were detected beyond 48 hours and within 14 days in a large proportion of patients (30% of recurrent AF and 60% of arrhythmias in pregnancy), with important implications for clinical assessment and decision-making.1-2 The findings add to the body of evidence on the limitations of commonly used short-duration 24–48-hour Holter monitoring and further reinforce the clinical value of continuous, uninterrupted monitoring up to 14 days with Zio ambulatory ECG devices across diverse patient populations.1-4

The findings presented at HRS 2026 reflect the growing clinical importance of atrial fibrillation (AF)—the most common arrhythmia5 and one associated with a fivefold increased risk of stroke6—where accurate detection is central to management, alongside increasing use of catheter ablation, where post-procedure rhythm assessment is critical to guide risk stratification and downstream clinical decisions.

They also highlight the importance of arrhythmia detection in pregnancy, where rising maternal cardiovascular risk and the 2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy7 have advanced pregnancy-specific management guidance, while approaches to arrhythmia detection and monitoring remain less well defined.

Detection of Post-Ablation AF Recurrence and Monitoring Duration Study: Short-Term Holter May Miss Arrhythmias1

Arrhythmia monitoring after catheter ablation of atrial fibrillation (AF) is used to identify recurrence and inform treatment. The optimal duration is not well defined. In a nationwide retrospective analysis of 11,051 patients who monitored with a Zio ambulatory ECG device in the year following AF ablation, the overall recurrence rate of AF was 21% and a substantial proportion of AF recurrence was detected beyond 48 hours and within 14 days. Notable findings include:  

AF recurrence would often be missed with 24-48-hour monitoring: With up to 14 days of continuous, uninterrupted monitoring using Zio ambulatory ECG, 26% of patients overall—and 29.8% of patients with paroxysmal AF—had their first detected AF recurrence beyond 48 hours, indicating that reliance on short-duration Holter monitoring would miss AF recurrence in a l considerable proportion of post-ablation patients.Up to 1 in 4 Misclassified: These data suggest that up to 1 in 4 patients with true AF recurrence could be misclassified as a false negative with short-duration Holter monitoring compared up to 14 days with Zio ambulatory ECG. These data provide new real-world evidence in a patient population where the clinical value of continuous, uninterrupted monitoring up to 14 days with Zio for post-ablation monitoring has previously not been well quantified. Reliance on short-term monitoring in clinical practice may result in missed AF recurrence, which has clinical implications for anticoagulation discontinuation based on recent studies such as the OCEAN (Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation) trial, which used a strategy of sequential cardiac monitoring of only 24-48 hours.8

“These data reinforce that monitoring approach and duration directly impact what is detected—and what is missed,” said Mintu Turakhia, MD, MS, Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm. Monitoring of 48 hours or less leads to false negatives of AF recurrence in 30% of those monitored in the year following-PVI. As AF burden and recurrence increase the risk of stroke and are directly actionable for clinical decisions regarding anticoagulation, antiarrhythmic, repeat ablation, and risk of heart failure — the data are clear that 14 days should be the minimum threshold for post-ablation monitoring.”

Pregnancy Study: Majority of Clinically Significant Arrhythmias Detected After 48 Hours2,9

In a retrospective analysis of pregnant patients undergoing extended monitoring using Zio ambulatory ECG devices, arrhythmias were present in 1 in 7 patients, but with 60% first detected after 48 hours—events that would be missed with commonly used short-duration 24–48-hour Holter monitoring.

Arrhythmias Detected in Pregnancy: Arrhythmias were detected in 37.7% of pregnant patients, the majority evaluated for symptoms such as palpitations (62.8%), showing that rhythm abnormalities can occur even in patients without structural or other forms of heart disease.1 in 7 Clinically Significant Arrhythmias9: Clinically significant arrhythmias were detected in 13.6% of patients, including AF ≥30 seconds, SVT ≥90 bpm and ≥30 seconds, VT ≥100 bpm and ≥4 beats, pause ≥3 seconds, and AV block (2nd deg. Mobitz II, high grade AVB, or complete heart block).Majority of Clinically Significant Arrhythmias9 Detected After 48 Hours: Most arrhythmias were detected after 48 hours (66.7% clinically significant; 59.6% overall). These data suggest that short-duration 24-48-hour Holter monitoring would fail to detect a substantial portion of clinically significant arrhythmias compared to up to 14 days of continuous, uninterrupted monitoring with Zio ambulatory ECG devices.99.2% Analyzable Time: Median analyzable time was 99.2%, indicating that nearly all recorded monitoring time produced usable heart rhythm data, demonstrating that high-quality ECG data can be obtained with continuous, uninterrupted monitoring up to 14 days with Zio ambulatory ECG devices in pregnant patients. These data provide new real-world evidence in a population where physiologic changes are associated with increased susceptibility to arrhythmias7 and cardiovascular disease remains the leading cause of pregnancy related death in the United States,10 underscoring the importance of accurate and timely detection where evidence on extended monitoring has been limited.

"Physiologic changes during pregnancy increase arrhythmia risk,7 with implications for both maternal and fetal health,” said Ridhima Kapoor, MD, Clinical Assistant Professor of Cardiovascular Medicine at Stanford University, and an investigator on the study and its presenting author. “This analysis demonstrates that arrhythmias occur in more than one-third of pregnant patients, with clinically significant events in nearly 1 in 7. Notably, the majority were identified after 48 hours of monitoring. This underscores the importance of extended cardiac monitoring to accurately capture arrhythmia burden and guide management."

Implications for Clinical Practice and Research

A growing body of large-scale real-world evidence has demonstrated the clinical value of continuous, uninterrupted monitoring up to 14 days with Zio ambulatory ECG devices, including higher diagnostic yield and lower repeat testing compared with short-duration 24–48-hour Holter and other ambulatory cardiac monitoring modalities.11,12

Additional real-world evidence from a large-scale analysis of more than 1 million patients, published in February this year in Heart Rhythm, the journal of the Heart Rhythm Society, demonstrates that 24–48-hour monitoring can miss actionable arrhythmias even in patients with frequent (i.e., daily) symptoms.13

Taken together, the totality of evidence—including new data in post-ablation and pregnancy populations strongly supports the progressive shift away from reliance on short-duration monitoring and toward 14-day continuous, uninterrupted, patch-based cardiac monitoring to better align clinical practice and the evidence base informing standards of care with a more complete assessment of arrhythmia burden.

iRhythm Differentiation

The clinical value of iRhythm is delivered through its integrated Zio platform combining patch-based ECG monitoring, AI-powered analysis, and data curation and validation by qualified cardiac technicians to deliver actionable insights that help clinicians make the right diagnosis the first time.

Data presented at HRS 2026 add to iRhythm’s comprehensive clinical evidence program, encompassing more than 140 original research manuscripts, insights derived from over 3 billion hours of curated heartbeat data, and over 12 million patient reports since the company’s inception14—underscoring an ongoing commitment to expanding evidence that supports improved patient outcomes.

About the iRhythm Studies Presented at HRS 2026

Detection of Atrial Fibrillation Recurrence and Monitoring Duration on Ambulatory Cardiac Monitoring: Implications for OCEAN Trial-Guided Anticoagulation Discontinuation1
Retrospective analysis of U.S. patients receiving Zio LTCM between 2018 and 2022 who had undergone catheter ablation for AF within the prior year. Of 709,083 patients with linked data, 11,051 met the inclusion criteria and were included in the study. AF types included paroxysmal AF (53%), persistent AF (36%), and unspecified AF (11%). The mean time to monitoring was 113 days post-ablation.

Frequency of Cardiac Arrhythmia Detection on Extended Ambulatory Cardiac ECG Monitoring During Pregnancy: Results from a Large National Sample2
Retrospective cohort study of 486 pregnant women aged 18-45 years undergoing extended ambulatory ECG monitoring. The study population had low baseline cardiovascular comorbidity. Of the 486 women in the study, 63% were monitored for palpitations, 25% had advanced maternal age (aged ≥35 years), and 24.9% had hypertensive disorders of pregnancy.

About iRhythm Holdings
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “anticipate,” “estimate,” “expect,” “intend,” “will,” “may,” “project,” “plan,” “believe,” “target,” and similar expressions that relate to future events or outcomes.

Forward-looking statements in this press release include, but are not limited to, statements regarding the significance and potential impact of the data presented; the clinical utility and performance of iRhythm’s Zio® ambulatory ECG monitoring devices and service; the potential to improve detection and assessment of arrhythmias, including in post-ablation and pregnancy populations; the potential to inform clinical decision-making, including anticoagulation management and risk stratification; and the potential for extended continuous monitoring to provide a more complete assessment of arrhythmia burden.

These statements are based on current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the timing, interpretation, and acceptance of clinical data; the ability to translate findings into clinical practice; regulatory and reimbursement developments; market adoption of iRhythm’s products and services; and the risks described in the section entitled “Risk Factors” in iRhythm’s most recent filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q.

These forward-looking statements speak only as of the date of this press release, and iRhythm undertakes no obligation to update them, except as required by law.

Media Contact:
Kassandra Perry
[email protected]

Investor Contact:
[email protected]

Turakhia MP et al. “Detection of Atrial Fibrillation Recurrence and Monitoring Duration on Ambulatory Cardiac Monitoring: Implications for OCEAN Trial-Guided Anticoagulation Discontinuation.” Heart Rhythm Society’s Annual Meeting, 2026. Chicago, Illinois.Kapoor R et al. “Frequency of Cardiac Arrhythmia Detection on Extended Ambulatory Cardiac ECG Monitoring During Pregnancy: Results from a Large National Sample.” Heart Rhythm Society’s Annual Meeting, 2026. Chicago, Illinois.The Zio AT device is not intended for use in critical care patients because the reporting timeliness is not consistent with life-threatening arrhythmias such as ventricular fibrillation. Refer to Zio AT Clinical Reference Manual for additional information. Do not use Zio AT for patients with symptomatic episodes where variations in cardiac performance could result in immediate danger to the patient or when real-time or in-patient monitoring should be prescribed.https://www.cdc.gov/heartdisease/atrial_fibrillation.htm. File name: CDC Afib.pdfFAQ About Atrial Fibrillation (AFib). American Heart Association. https://www.heart.org/-/media/Files/Health-Topics/Atrial-Fibrillation/FAQ-About-AFib.pdf [accessed April 2026]2023 HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy. Heart Rhythm Society. Heart Rhythm. 2023. https://www.heartrhythmjournal.com/article/S1547-5271(23)02246-4/fulltext [accessed April 2026]Verma A, Birnie DH, Jiang C, Heidbüchel H, Hindricks G, Kirchhof P, Healey JS, Wang Y, Dagres N, Deyell MW, et al; OCEAN Investigators. Antithrombotic therapy after successful catheter ablation for atrial fibrillation. N Engl J Med. 2026;394:323–332. doi: 10.1056/NEJMoa2509688Clinically significant arrhythmias were defined as AF ≥30 seconds; SVT ≥90 bpm and ≥30 seconds; VT ≥100 bpm and ≥4 beats; ventricular fibrillation; pause ≥3 seconds; or AV block (any second-degree or complete heart block). Definitions reflect study-specific criteria; determinations of clinical significance are not made by the Zio ambulatory ECG device or service.American Heart Association. Heart Disease and Stroke Statistics—2024 Update: A Report From the American Heart Association. Circulation. 2024. 
https://www.ahajournals.org/doi/10.1161/CIR.0000000000001209 [accessed April 2026]Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring Strategies in Medicare Beneficiaries. Heart Rhythm Society. American Heart Journal. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002 [accessed April 2026]Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients. Heart Rhythm Society. American Journal of Managed Care. 2025. https://www.ajmc.com/view/assessment-of-variation-in-ambulatory-cardiac-monitoring-among-commercially-insured-patients [accessed April 2026]Relationship of Symptom Frequency and Symptom-Rhythm Correlation to Arrhythmia Type and Time to Detection: Insights from Ambulatory ECG Monitoring in Over 1 Million Patients. Heart Rhythm Society. Heart Rhythm. 2025. https://www.heartrhythmjournal.com/article/S1547-5271(25)03049-8/fulltext [accessed April 2026]Data on file. iRhythm Technologies, 2026; based on patient reports posted since company inception through December 31, 2025 and hours of curated ECG data since company inception through March 2026.

April 30, 2026 16:05 ET  | Source: iRhythm

SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026.

First Quarter 2026 Financial Highlights

Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, respectively, compared to first quarter 2025Unrestricted cash, cash equivalents, and marketable securities of $549.6 million as of March 31, 2026Increased fiscal year 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin to 12.0% to 13.0% Recent Operational Highlights

Delivered another strong quarter, demonstrated by robust volume led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international marketsPresented data at ACC and HRS further demonstrating the benefits of iRhythm’s Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform “We delivered a strong start to 2026, with continued revenue growth reflecting durable demand for our platform and increasing adoption across multiple care settings,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “We are increasingly diversified across channels, with meaningful contributions from Zio monitor, Zio AT, innovative partnerships, and international markets. As we advance our AI-enabled capabilities and expand into earlier detection, we believe we are unlocking a significantly larger opportunity to improve patient outcomes while providing an integrated solution that lowers the total cost of cardiac care.”

First Quarter 2026 Financial Results
Revenue for the first quarter of 2026 was $199.4 million, up 25.7% from $158.7 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.

Gross profit for the first quarter of 2026 was $141.4 million, up 29.4% from $109.2 million during the same period in 2025, while gross margin was 70.9%, a 210-basis point improvement compared to first quarter 2025. The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, as well as scale benefits from higher volumes.

Operating expenses for the first quarter of 2026 were $157.5 million, compared to $141.8 million for the same period in 2025. Adjusted operating expenses for the first quarter of 2026 were $153.5 million, compared to $140.4 million during the same period in 2025. The increase in adjusted operating expenses, period over period, was driven by an increase in volume-related costs to serve, litigation-related expenses and investments to drive future revenue growth.

Net loss for the first quarter of 2026 was $13.9 million, or a net loss of $0.43 per diluted share, compared with net loss of $30.7 million, or net loss of $0.97 per diluted share, for the same period in 2025. Adjusted net loss for the first quarter of 2026 was $11.3 million, or net loss of $0.35 per diluted share, compared with an adjusted net loss of $30.3 million, or net loss of $0.95 per diluted share, for the same period in 2025. The decrease in net loss was primarily driven by our revenue growth and operating leverage achieved through implementation of efficiency initiatives.

Unrestricted cash, cash equivalents, and marketable securities were $549.6 million as of March 31, 2026.

2026 Annual Guidance
For the full year 2026, iRhythm expects revenue between $875 million and $885 million and adjusted EBITDA margin between 12% and 13%, reflecting continued volume-led growth, gross margin expansion, and operating leverage while maintaining disciplined investment in innovation and market expansion.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted EBITDA margin, adjusted net loss, adjusted net loss per share, adjusted operating expenses and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation expense, changes in fair value of strategic investments, impairment and restructuring charges, business transformation costs, certain intellectual property litigation expenses and settlements, and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, expansion into new health programs, international market expansion, anticipated productivity and quality improvements, anticipated demand for our products and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about April 30, 2026. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Contact
[email protected]

Media Contact
Kassandra Perry
[email protected]

IRHYTHM HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
(unaudited)
     March 31, 2026 December 31, 2025Assets   Current assets:   Cash and cash equivalents$240,146  $236,012 Marketable securities 309,474   347,751 Accounts receivable, net 80,863   75,706 Inventory 23,800   21,634 Prepaid expenses and other current assets 26,275   21,662 Total current assets 680,558   702,765 Property and equipment, net 156,704   151,599 Operating lease right-of-use assets 40,324   41,827 Restricted cash 8,358   8,358 Goodwill 862   862 Long-term strategic investments 72,860   69,913 Other assets 46,699   44,718 Total assets$1,006,365  $1,020,042 Liabilities and Stockholders’ Equity   Current liabilities:   Accounts payable$8,559  $2,256 Accrued liabilities 102,342   128,747 Deferred revenue 4,056   4,201 Operating lease liabilities, current portion 16,793   16,686 Total current liabilities 131,750   151,890 Long-term senior convertible notes 650,313   649,504 Other noncurrent liabilities 907   908 Operating lease liabilities, noncurrent portion 62,185   64,994 Total liabilities 845,155   867,296 Stockholders’ equity:   Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025 —   — Common stock, $0.001 par value – 100,000 shares authorized; 33,083 shares issued and 32,854 shares outstanding at March 31, 2026, respectively; and 32,526 shares issued and 32,297 shares outstanding at December 31, 2025, respectively 33   32 Additional paid-in capital 1,003,514   980,757 Accumulated other comprehensive income 42   403 Accumulated deficit (817,379)  (803,446)Treasury stock, at cost; 229 shares at March 31, 2026 and December 31, 2025 (25,000)  (25,000)Total stockholders’ equity 161,210   152,746 Total liabilities and stockholders’ equity$1,006,365  $1,020,042  IRHYTHM HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
     Three Months Ended March 31,   2026   2025 Revenue, net $199,390  $158,677 Cost of revenue  58,037   49,461 Gross profit  141,353   109,216 Operating expenses:    Research and development  21,358   21,519 Acquired in-process research and development  296   296 Selling, general and administrative  135,884   119,957 Total operating expenses  157,538   141,772 Loss from operations  (16,185)  (32,556)Interest and other income, net:    Interest income  4,879   4,919 Interest expense  (3,290)  (3,273)Other income, net  1,163   875 Total interest and other income, net  2,752   2,521 Loss before income taxes  (13,433)  (30,035)Income tax provision  500   665 Net loss $(13,933) $(30,700)Net loss per common share, basic and diluted $(0.43) $(0.97)Weighted-average shares, basic and diluted  32,507   31,590  IRHYTHM HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share data)
(unaudited)
     Three Months Ended March 31,   2026   2025 Adjusted EBITDA reconciliation*    Net loss, as reported1 $(13,933) $(30,700)Interest expense  3,290   3,273 Interest income  (4,879)  (4,919)Changes in fair value of strategic investments  (1,447)  (843)Income tax provision  500   665 Depreciation and amortization  5,042   5,210 Stock-based compensation  21,491   23,344 Business transformation costs  346   503 Intellectual property litigation costs2  3,689   832 Adjusted EBITDA $14,099  $(2,635)     Adjusted net loss reconciliation*    Net loss, as reported1 $(13,933) $(30,700)Business transformation costs  346   503 Intellectual property litigation costs2  3,689   832 Changes in fair value of strategic investments  (1,447)  (843)Tax effect of adjustments3  —   (91)Adjusted net loss $(11,345) $(30,299)     Adjusted net loss per share reconciliation*    Net loss per share, as reported1 $(0.43) $(0.97)Business transformation costs per share  0.01   0.02 Intellectual property litigation costs per share2  0.11   0.03 Changes in fair value of strategic investments per share  (0.04)  (0.03)Tax effect of adjustments per share3  —   — Adjusted net loss per share $(0.35) $(0.95)Weighted-average shares, basic and diluted  32,507   31,590      Adjusted operating expenses reconciliation*    Operating expenses, as reported $157,538  $141,772 Business transformation costs  (346)  (503)Intellectual property litigation costs2  (3,689)  (832)Adjusted operating expenses $153,503  $140,437           *Certain numbers expressed may not sum due to rounding.
1 Net loss for the three months ended March 31, 2026 and 2025, includes $0.3 million of acquired in-process research and development expense.
2 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.
3 Income tax impact of Non-GAAP adjustments listed.

  Three Months Ended March 31,   2026   2025 Free cash flow reconciliation*    Net cash used in operating activities $(26,173) $(7,891)Purchases of property and equipment  (6,905)  (9,419)Free cash flow $(33,078) $(17,310)          *Certain numbers expressed may not sum due to rounding.

iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: iRhythm Holdings, Inc. (IRTC - Free Report) iRhythm Holdings is a leader in ambulatory cardiac monitoring (ACM), operating a device-enabled digital diagnostics platform that integrates wearable biosensors (Zio), FDA-cleared AI algorithms, and enterprise clinical workflows delivered through EHR systems . Unlike legacy Holter and event monitors, iRhythm’s Zio platform captures continuous multi-day ECG data, which is processed using deep-learning algorithms and delivered as clinically actionable digital reports.

IRTC is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. IRTC has a Momentum Style Score of A, and shares are up 1.7% over the past four weeks.

Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.31 to $0.10 per share. IRTC also boasts an average earnings surprise of +377.6%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IRTC should be on investors' short list.

iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 19, 2026 16:05 ET  | Source: iRhythm

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences.

William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 8:00 a.m. CT (6:00 a.m. PT)
Truist Securities MedTech Conference on June 16, 2026, at 2:20 p.m. ET (11:20 a.m. PT)

Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
[email protected]

Media Contact
Kassandra Perry
[email protected]